Sector News

Bloomberg: Sale of OTC specialist Omega could top $5.3B with bids from Bayer, Sanofi

September 2, 2014
Life sciences

What’s an OTC drugmaker worth in the race to the top of the consumer healthcare space? Potentially more than $5.3 billion, if that drugmaker is Belgium’s Omega Pharma.

The up-for-sale company has so far drawn interest from suitors including Perrigo ($PRGO) and Boehringer Ingelheim, and the big guns – Bayer and Sanofi ($SNY) – may get involved, too, Bloomberg‘s sources say. According to those sources, the sale – still in its early stages – could bring in more than €4 billion.

With €1.2 billion in first-half sales this year, Omega could add some top-line firepower for any drugmaker looking to build its presence in the consumer health arena. The company boasts about 2,000 brands, according to its website, including painkiller Solpadeine.

Bayer and Sanofi have both shown quite a bit of recent interest in doing just that. Marijn Dekkers, the German pharma’s CEO, has said many times that his company’s aim is to be the world’s OTC leader, a goal it furthered with a May deal to pick up Merck’s ($MRK) consumer unit for $14.2 billion.

Sanofi, too, has beefed up its consumer lineup considerably over the past several years, more than doubling its sales in that department between 2008 and 2012. That growth spurt included a $1.9 billion buyout of U.S.-based Chattem and a key OTC launch for allergy med Allegra.

Perrigo hasn’t shied away from M&A lately, either, though last year’s $8.6 billion deal for Irish drugmaker Elan ($ELN) didn’t further any OTC aims. Instead, the then-Michigan-based company picked up a new Dublin address in an inversion deal that slashed its tax rates.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).